vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and MODIV INDUSTRIAL, INC. (MDV). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $11.1M, roughly 1.7× MODIV INDUSTRIAL, INC.). MODIV INDUSTRIAL, INC. runs the higher net margin — 11.0% vs -0.8%, a 11.8% gap on every dollar of revenue. On growth, MODIV INDUSTRIAL, INC. posted the faster year-over-year revenue change (-5.6% vs -25.7%). Over the past eight quarters, MODIV INDUSTRIAL, INC.'s revenue compounded faster (-3.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.
CTMX vs MDV — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $11.1M |
| Net Profit | $-154.0K | $1.2M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 45.8% |
| Net Margin | -0.8% | 11.0% |
| Revenue YoY | -25.7% | -5.6% |
| Net Profit YoY | 97.6% | -22.0% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $11.7M | ||
| Q2 25 | $18.7M | $11.8M | ||
| Q1 25 | $50.9M | $11.8M | ||
| Q4 24 | $38.1M | $11.7M | ||
| Q3 24 | $33.4M | $11.7M | ||
| Q2 24 | $25.1M | $11.4M | ||
| Q1 24 | $41.5M | $12.0M |
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $1.0M | ||
| Q2 25 | $-154.0K | $-2.0M | ||
| Q1 25 | $23.5M | $829.0K | ||
| Q4 24 | $18.9M | $1.6M | ||
| Q3 24 | $5.7M | $-587.0K | ||
| Q2 24 | $-6.5M | $1.3M | ||
| Q1 24 | $13.8M | $3.7M |
| Q4 25 | — | 45.8% | ||
| Q3 25 | — | 41.4% | ||
| Q2 25 | -6.9% | 9.8% | ||
| Q1 25 | 44.4% | 40.2% | ||
| Q4 24 | 46.4% | 45.4% | ||
| Q3 24 | 12.3% | 42.0% | ||
| Q2 24 | -33.7% | 44.6% | ||
| Q1 24 | 28.1% | 55.6% |
| Q4 25 | — | 11.0% | ||
| Q3 25 | — | 9.0% | ||
| Q2 25 | -0.8% | -17.1% | ||
| Q1 25 | 46.2% | 7.0% | ||
| Q4 24 | 49.6% | 13.3% | ||
| Q3 24 | 17.2% | -5.0% | ||
| Q2 24 | -26.0% | 11.6% | ||
| Q1 24 | 33.3% | 31.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $-0.32 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $14.4M |
| Total DebtLower is stronger | — | $261.5M |
| Stockholders' EquityBook value | $119.9M | $162.7M |
| Total Assets | $175.1M | $476.5M |
| Debt / EquityLower = less leverage | — | 1.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | $49.0M | $5.8M | ||
| Q1 25 | $47.6M | $6.2M | ||
| Q4 24 | $38.1M | $11.5M | ||
| Q3 24 | $40.6M | $6.8M | ||
| Q2 24 | $43.2M | $18.9M | ||
| Q1 24 | $36.2M | $18.4M |
| Q4 25 | — | $261.5M | ||
| Q3 25 | — | $279.7M | ||
| Q2 25 | — | $279.7M | ||
| Q1 25 | — | $279.7M | ||
| Q4 24 | — | $279.8M | ||
| Q3 24 | — | $279.7M | ||
| Q2 24 | — | $279.7M | ||
| Q1 24 | — | $279.6M |
| Q4 25 | — | $162.7M | ||
| Q3 25 | — | $164.8M | ||
| Q2 25 | $119.9M | $165.6M | ||
| Q1 25 | $25.0M | $171.1M | ||
| Q4 24 | $-456.0K | $190.1M | ||
| Q3 24 | $-23.5M | $186.3M | ||
| Q2 24 | $-31.2M | $187.0M | ||
| Q1 24 | $-31.7M | $188.0M |
| Q4 25 | — | $476.5M | ||
| Q3 25 | — | $499.6M | ||
| Q2 25 | $175.1M | $498.9M | ||
| Q1 25 | $98.5M | $506.8M | ||
| Q4 24 | $120.5M | $507.8M | ||
| Q3 24 | $139.0M | $507.4M | ||
| Q2 24 | $159.2M | $519.5M | ||
| Q1 24 | $184.7M | $522.5M |
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 1.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $15.0M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 12.34× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $4.1M | ||
| Q2 25 | $-15.8M | $3.9M | ||
| Q1 25 | $-21.0M | $3.0M | ||
| Q4 24 | $-19.9M | $18.2M | ||
| Q3 24 | $-20.7M | $5.1M | ||
| Q2 24 | $-19.5M | $4.7M | ||
| Q1 24 | $-26.0M | $3.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 12.34× | ||
| Q3 25 | — | 3.95× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | 3.68× | ||
| Q4 24 | -1.05× | 11.72× | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | 3.55× | ||
| Q1 24 | -1.89× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
MDV
Segment breakdown not available.
